Innocan Pharma Corp
CNSX:INNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Innocan Pharma Corp
Other Current Liabilities
Innocan Pharma Corp
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Innocan Pharma Corp
CNSX:INNO
|
Other Current Liabilities
$386k
|
CAGR 3-Years
8%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Other Current Liabilities
$5.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Other Current Liabilities
$18.1m
|
CAGR 3-Years
41%
|
CAGR 5-Years
31%
|
CAGR 10-Years
48%
|
|
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
Other Current Liabilities
$4.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
19%
|
CAGR 10-Years
17%
|
|
|
Scisparc Ltd
NASDAQ:SPRC
|
Other Current Liabilities
$341k
|
CAGR 3-Years
-7%
|
CAGR 5-Years
103%
|
CAGR 10-Years
28%
|
|
|
T
|
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
|
Other Current Liabilities
₪5.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Innocan Pharma Corp
Glance View
InnoCan Pharma Corp. focuses on the development and sale of CBD-integrated pharmaceuticals including topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
See Also
What is Innocan Pharma Corp's Other Current Liabilities?
Other Current Liabilities
386k
USD
Based on the financial report for Dec 31, 2025, Innocan Pharma Corp's Other Current Liabilities amounts to 386k USD.
What is Innocan Pharma Corp's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-44%
Over the last year, the Other Current Liabilities growth was -75%. The average annual Other Current Liabilities growth rates for Innocan Pharma Corp have been 8% over the past three years , -44% over the past five years .
